172 related articles for article (PubMed ID: 18711702)
1. Hypermethylation of E-cadherin is an independent predictor of improved survival in head and neck squamous cell carcinoma.
Marsit CJ; Posner MR; McClean MD; Kelsey KT
Cancer; 2008 Oct; 113(7):1566-71. PubMed ID: 18711702
[TBL] [Abstract][Full Text] [Related]
2. The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage.
Pannone G; Santoro A; Feola A; Bufo P; Papagerakis P; Lo Muzio L; Staibano S; Ionna F; Longo F; Franco R; Aquino G; Contaldo M; De Maria S; Serpico R; De Rosa A; Rubini C; Papagerakis S; Giovane A; Tombolini V; Giordano A; Caraglia M; Di Domenico M
Curr Cancer Drug Targets; 2014; 14(2):115-27. PubMed ID: 24274398
[TBL] [Abstract][Full Text] [Related]
3. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
4. Promoter Hypermethylation Profiling Identifies Subtypes of Head and Neck Cancer with Distinct Viral, Environmental, Genetic and Survival Characteristics.
Choudhury JH; Ghosh SK
PLoS One; 2015; 10(6):e0129808. PubMed ID: 26098903
[TBL] [Abstract][Full Text] [Related]
5. NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas.
Virani S; Bellile E; Bradford CR; Carey TE; Chepeha DB; Colacino JA; Helman JI; McHugh JB; Peterson LA; Sartor MA; Taylor JM; Walline HM; Wolf GT; Rozek LS
BMC Cancer; 2015 Oct; 15():825. PubMed ID: 26518708
[TBL] [Abstract][Full Text] [Related]
6. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylation of collagen α2 (I) gene (COL1A2) is an independent predictor of survival in head and neck cancer.
Misawa K; Kanazawa T; Misawa Y; Imai A; Endo S; Hakamada K; Mineta H
Cancer Biomark; 2011-2012; 10(3-4):135-44. PubMed ID: 22674299
[TBL] [Abstract][Full Text] [Related]
8.
Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; Franzen A; Dietrich J; Kristiansen G; Bootz F; Schröck A; Dietrich D
Clin Epigenetics; 2017; 9():12. PubMed ID: 28174607
[TBL] [Abstract][Full Text] [Related]
9. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer.
Misawa Y; Misawa K; Kanazawa T; Uehara T; Endo S; Mochizuki D; Yamatodani T; Carey TE; Mineta H
Cancer; 2014 Jan; 120(2):205-13. PubMed ID: 24122450
[TBL] [Abstract][Full Text] [Related]
11. Head and neck squamous cell carcinoma: mismatch repair immunohistochemistry and promoter hypermethylation of hMLH1 gene.
Tawfik HM; El-Maqsoud NM; Hak BH; El-Sherbiny YM
Am J Otolaryngol; 2011; 32(6):528-36. PubMed ID: 21353335
[TBL] [Abstract][Full Text] [Related]
12. Increased microsatellite instability and epigenetic inactivation of the hMLH1 gene in head and neck squamous cell carcinoma.
Zuo C; Zhang H; Spencer HJ; Vural E; Suen JY; Schichman SA; Smoller BR; Kokoska MS; Fan CY
Otolaryngol Head Neck Surg; 2009 Oct; 141(4):484-90. PubMed ID: 19786217
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer.
Misawa K; Mochizuki D; Imai A; Endo S; Mima M; Misawa Y; Kanazawa T; Carey TE; Mineta H
Oncotarget; 2016 May; 7(18):26087-98. PubMed ID: 27027429
[TBL] [Abstract][Full Text] [Related]
14. Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance.
Carvalho AL; Henrique R; Jeronimo C; Nayak CS; Reddy AN; Hoque MO; Chang S; Brait M; Jiang WW; Kim MM; Claybourne Q; Goldenberg D; Khan Z; Khan T; Westra WH; Sidransky D; Koch W; Califano JA
Clin Cancer Res; 2011 Jul; 17(14):4782-9. PubMed ID: 21628494
[TBL] [Abstract][Full Text] [Related]
15. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR
BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of human mutL homolog 1 and mutS homolog 2 genes in head and neck squamous cell carcinoma tumors and leukoplakia samples by promoter hypermethylation and its relation with microsatellite instability phenotype.
Sengupta S; Chakrabarti S; Roy A; Panda CK; Roychoudhury S
Cancer; 2007 Feb; 109(4):703-12. PubMed ID: 17219447
[TBL] [Abstract][Full Text] [Related]
17. O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma.
Zuo C; Ai L; Ratliff P; Suen JY; Hanna E; Brent TP; Fan CY
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):967-75. PubMed ID: 15184253
[TBL] [Abstract][Full Text] [Related]
18. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.
Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H
Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.
Misawa K; Misawa Y; Kanazawa T; Mochizuki D; Imai A; Endo S; Carey TE; Mineta H
Clin Exp Metastasis; 2016 Feb; 33(2):187-95. PubMed ID: 26572146
[TBL] [Abstract][Full Text] [Related]
20. Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs.
Graziano F; Arduini F; Ruzzo A; Mandolesi A; Bearzi I; Silva R; Muretto P; Testa E; Mari D; Magnani M; Scartozzi M; Cascinu S
Ann Oncol; 2004 Mar; 15(3):489-92. PubMed ID: 14998854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]